The decision won’t affect the Illumina-Grail relationship, with Illumina having already divested the cancer screening company ...

Illumina has a long history of driving advancements in genomics, providing the tools and technologies that have ...

(NASDAQ:ILMN) said it welcomes the European Court of Justice’s (ECJ’s) judgment ruling that the European Commission did not have jurisdiction over Illumina’s acquisition of GRAIL. The judgment ...

Lawmakers say the companies are part of a "military-civil fusion" by China to modernize China's military by collecting huge ...

Illumina has a long history of driving advancements in genomics, providing the tools and technologies that have revolutionized many applications, including agriculture. Biosearch Technologies, part of ...

Genomics is on the brink of revolutionizing healthcare with breakthroughs that could redefine treatment and diagnosis. As ...

Illumina completed the spin-off of GRAIL in June 2024, retaining a 14.5% stake. The company is refocusing on its core DNA sequencing business, targeting high single-digit revenue growth by 2027.

Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, welcomes the European Court of Justice's (ECJ's) judgment today ruling that the European Commission ...

2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced Food and Drug Administration (FDA) approval of its in vitro ...

BENGALURU: Illumina, a global leader in DNA sequencing and array-based technologies, announced it will establish a Global CapabilityCenter in Bengaluru to expand its technology workforce in ...

Report on how AI is driving market transformation- The global bioinformatics market size is estimated to grow by USD ...